Deciphering the mechanism of PSORI-CM02 in suppressing keratinocyte proliferation through the mTOR/HK2/glycolysis axis.
PSORI-CM02
hexokinase 2
mammalian target of rapamycin
proliferating keratinocytes
psoriasis
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
01
2023
accepted:
30
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Hyperplasia of epidermal keratinocytes that depend on glycolysis is a new hallmark of psoriasis pathogenesis. Our previous studies demonstrated that PSORI-CM02 could halt the pathological progression of psoriasis by targeting inflammatory response and angiogenesis, but its effect(s) and mechanism(s) on proliferating keratinocytes remained unclear. In this study, we aim to identify components of PSORI-CM02 that are absorbed into the blood and to determine the effect(s) of PSORI-CM02 on keratinocyte proliferation and its molecular mechanism(s). We used the immortalized human epidermal keratinocyte cell line, HaCaT, as an
Identifiants
pubmed: 37089953
doi: 10.3389/fphar.2023.1152347
pii: 1152347
pmc: PMC10119413
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1152347Informations de copyright
Copyright © 2023 Wang, Tang, Huang, Wu, Deng, Chen, Mei, Chen, Burgering and Lu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Life Sci. 2022 Dec 15;311(Pt B):121201
pubmed: 36400203
J Leukoc Biol. 2020 Aug;108(2):485-491
pubmed: 32170886
Glia. 2020 May;68(5):1031-1045
pubmed: 31793691
Front Oncol. 2022 Jul 26;12:785345
pubmed: 35957872
Phytother Res. 2021 Jul;35(7):3812-3820
pubmed: 33856720
Nat Commun. 2020 Apr 20;11(1):1869
pubmed: 32313017
Theranostics. 2022 Apr 24;12(7):3518-3533
pubmed: 35547764
J Biol Chem. 2002 Feb 1;277(5):3334-41
pubmed: 11724794
Clin Rev Allergy Immunol. 2018 Dec;55(3):295-311
pubmed: 28780731
Evid Based Complement Alternat Med. 2020 Apr 10;2020:6981520
pubmed: 32351601
J Cell Physiol. 2018 Mar;233(3):2434-2443
pubmed: 28776671
BMJ. 2020 May 28;369:m1590
pubmed: 32467098
J Ethnopharmacol. 2012 May 7;141(1):290-300
pubmed: 22391142
Physiol Rev. 2021 Jul 1;101(3):1371-1426
pubmed: 33599151
Front Pharmacol. 2021 Oct 18;12:765790
pubmed: 34733164
Evid Based Complement Alternat Med. 2021 Apr 7;2021:6623464
pubmed: 33880124
Int J Stem Cells. 2021 Feb 28;14(1):85-93
pubmed: 33632981
Cell Death Dis. 2022 Jan 24;13(1):81
pubmed: 35075118
J Oncol. 2022 Aug 28;2022:7498771
pubmed: 36072982
J Invest Dermatol. 2021 Nov;141(11):2656-2667.e11
pubmed: 34004188
Foods. 2021 Mar 09;10(3):
pubmed: 33803279
Biol Pharm Bull. 2016;39(11):1830-1838
pubmed: 27803454
Mol Med Rep. 2014 Mar;9(3):935-40
pubmed: 24398569
Nat Med. 2018 May;24(5):617-627
pubmed: 29662201
Front Immunol. 2021 Apr 30;12:649591
pubmed: 33995368
Semin Cancer Biol. 2023 May;90:1-14
pubmed: 36706846
Mol Med Rep. 2015 Nov;12(5):6745-51
pubmed: 26502751
J Biol Chem. 1994 Jan 28;269(4):3081-7
pubmed: 8300643
Theranostics. 2022 Aug 29;12(14):6395-6408
pubmed: 36168616
JAMA. 2020 May 19;323(19):1945-1960
pubmed: 32427307
Mol Carcinog. 2019 Apr;58(4):533-543
pubmed: 30499613
Molecules. 2017 Apr 22;22(4):
pubmed: 28441723
Front Immunol. 2018 Jan 08;8:1767
pubmed: 29358932
J Ethnopharmacol. 2021 Dec 5;281:114571
pubmed: 34464701
J Ethnopharmacol. 2020 Nov 15;262:113214
pubmed: 32736045
Bioorg Med Chem Lett. 2017 Dec 15;27(24):5485-5489
pubmed: 29107540
Biosci Rep. 2020 Mar 27;40(3):
pubmed: 32039440
Phytomedicine. 2019 Nov;64:153054
pubmed: 31401494
Cell Rep. 2016 Feb 23;14(7):1590-1601
pubmed: 26876179
Biomed Pharmacother. 2019 Feb;110:265-274
pubmed: 30513504
Biosci Rep. 2018 Feb 21;38(1):
pubmed: 29298880
Oncol Rep. 2015 Mar;33(3):1284-90
pubmed: 25522911
Life Sci. 2020 Feb 15;243:117231
pubmed: 31887296